Kamada KMDA
NASDAQ KMDA
$8.20 -0.09 (-1.09%)
As of: Sep 9, 2026 · 3:37 PM EDT

Kamada (KMDA) Cost of Revenue (2012 - 2026)

Kamada's (KMDA) quarterly Cost of Revenue came in at $32.5 million in Q2 2026, up 25.67% on a YoY basis from $25.8 million in Q2 2025, and up 24.23% quarter-over-quarter from $26.1 million in Q1 2026.

Analysis

Kamada (KMDA) Cost of Revenue (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Cost of Revenue for 15 consecutive years, with $32.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cost of Revenue rose 25.67% year-over-year to $32.5 million; the trailing twelve-month figure through Jun 2026 stood at $113.5 million (up 18.79% YoY), and the FY2025 full-year result was $104.1 million, up 14.36% from the prior year.
  • Cost of Revenue advanced to $32.5 million in Q2 2026 per KMDA's latest filing, from $26.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $32.5 million in Q2 2026 and bottomed at $16.3 million in Q2 2022.
  • Historically, Cost of Revenue has averaged $23.5 million across 5 years, with a median of $23.2 million in 2023.
  • The widest YoY moves for Cost of Revenue: up 40.72% in 2023, down 26.96% in 2023.
  • Over 5 years, Cost of Revenue stood at $30.1 million in 2022, then declined by 26.96% to $22.0 million in 2023, then decreased by 0.21% to $22.0 million in 2024, then advanced by 26.11% to $27.7 million in 2025, then advanced by 17.12% to $32.5 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods registered $32.5 million, $26.1 million, and $27.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Amgen 211.77 Bn 197.79 Bn 7.24 Bn 2.81 Bn
2 Gilead Sciences 181.13 Bn 177.95 Bn 6.22 Bn 1.58 Bn
3 Vertex Pharmaceuticals 132.24 Bn 124.39 Bn 2.84 Bn 489.20 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.89 Bn 3.93 Bn 360.70 Mn
5 Argenx Se 61.56 Bn 56.38 Bn 1.37 Bn 145.00 Mn
6 Moderna 54.38 Bn 49.24 Bn 52.00 Mn 93.00 Mn
7 Alnylam Pharmaceuticals 34.44 Bn 31.13 Bn 992.69 Mn 298.26 Mn
8 Biogen 31.17 Bn 29.89 Bn 1.96 Bn 776.90 Mn
9 Roivant Sciences 30.12 Bn 30.12 Bn 1.16 Mn 284,000.00
10 Kamada 473.28 Mn 403.14 Mn 22.47 Mn 32.45 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 32.45 Mn
Mar 31, 2026 26.12 Mn
Dec 31, 2025 27.71 Mn
Sep 30, 2025 27.25 Mn
Jun 30, 2025 25.83 Mn
Mar 31, 2025 23.27 Mn
Dec 31, 2024 21.97 Mn
Sep 30, 2024 24.51 Mn
Jun 30, 2024 23.52 Mn
Mar 31, 2024 20.99 Mn
Dec 31, 2023 22.02 Mn
Sep 30, 2023 23.13 Mn
Jun 30, 2023 23.01 Mn
Mar 31, 2023 18.87 Mn
Dec 31, 2022 30.15 Mn
Sep 30, 2022 19.35 Mn
Jun 30, 2022 16.35 Mn
Mar 31, 2022 16.79 Mn
Dec 31, 2021 24.87 Mn
Sep 30, 2021 17.30 Mn